Academic Journal
Comparative study of antibiotic resistance and virulence profiles of exoU and exoS Pseudomonas aeruginosa isolates from urinary tract infections and microbial keratitis in Bangladesh and India.
| Τίτλος: | Comparative study of antibiotic resistance and virulence profiles of exoU and exoS Pseudomonas aeruginosa isolates from urinary tract infections and microbial keratitis in Bangladesh and India. |
|---|---|
| Συγγραφείς: | Akter T; School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW, 2052, Australia. t.akter@unsw.edu.au.; Microbial Biotechnology Division, National Institute of Biotechnology (NIB), Dhaka, 1349, Bangladesh. t.akter@unsw.edu.au., Islam S; Department of Biotechnology, Faculty of Natural Science, Norwegian University of Science and Technology, Trondheim, 7034, Norway., Haider AM; Department of Microbiology, Primeasia University, Banani, Dhaka, 1213, Bangladesh., Ahmed R; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, 7034, Norway., Fatema K; Department of Microbiology, Primeasia University, Banani, Dhaka, 1213, Bangladesh., Hoque MM; Department of Microbiology, Primeasia University, Banani, Dhaka, 1213, Bangladesh., Stapleton F; School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW, 2052, Australia., Willcox M; School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, NSW, 2052, Australia. |
| Πηγή: | World journal of microbiology & biotechnology [World J Microbiol Biotechnol] 2026 Oct 12; Vol. 42 (10). Date of Electronic Publication: 2026 Oct 12. |
| Τύπος έκδοσης: | Journal Article; Comparative Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer Country of Publication: Germany NLM ID: 9012472 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-0972 (Electronic) Linking ISSN: 09593993 NLM ISO Abbreviation: World J Microbiol Biotechnol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2005- : Berlin : Springer Original Publication: Oxford, OX, UK : Published by Rapid Communications of Oxford Ltd in association with UNESCO and in collaboration with the International Union of Microbiological Societies, c1990- |
| Ιατρικοί όροι (MeSH): | Urinary Tract Infections*/microbiology , Pseudomonas aeruginosa*/drug effects , Pseudomonas aeruginosa*/genetics , Pseudomonas aeruginosa*/pathogenicity , Pseudomonas aeruginosa*/isolation & purification , Pseudomonas Infections*/microbiology , Keratitis*/microbiology , Drug Resistance, Bacterial*/genetics , Bacterial Proteins*/genetics , Bacterial Toxins*/genetics, Anti-Bacterial Agents/pharmacology ; Virulence Factors/genetics ; Virulence/genetics ; Ciprofloxacin/pharmacology ; Drug Resistance, Multiple, Bacterial/genetics ; Levofloxacin/pharmacology ; Humans ; Bangladesh ; India ; Microbial Sensitivity Tests ; Whole Genome Sequencing ; Pseudomonas aeruginosa Exotoxin A ; Mutation ; Genome, Bacterial |
| Περίληψη: | Pseudomonas aeruginosa is an important opportunistic pathogen in urinary tract infections (UTIs) and microbial keratitis (MK), but differences in resistance and virulence between exoU and exoS P. aeruginosa isolates across regions and infection sites remain poorly understood. This study compared antibiotic resistance and virulence profiles of exoU and exoS P. aeruginosa isolates from Bangladeshi and Indian UTIs, and from Indian UTIs and MK collections. A total of 23 Bangladeshi UTI isolates were analyzed by broth microdilution for susceptibility to ciprofloxacin, levofloxacin, gentamicin, and tobramycin, and by whole-genome sequencing (WGS) to identify resistance-associated mutations, acquired resistance genes, and virulence factors. These WGS data were compared with 15 publicly available Indian UTI genomes, while the Indian UTI genomes were compared with 19 publicly available Indian MK genomes. In the Bangladeshi UTI cohort, exoU isolates showed greater resistance to fluoroquinolones and aminoglycosides than exoS isolates. Comparative analysis of Bangladeshi versus Indian UTI isolates and Indian UTI versus MK isolates showed that exoU isolates carried a burden of resistance mutations, including enrichment of GyrA Thr83Ile, ParE Asp533Glu, MexR Val126Glu, MexB Ser1041Glu, and MexC Ala262Glu. Aminoglycoside-associated substitutions FusA2 Gln161Leu and ParR Leu153Arg and Ser170Asn were more common in exoU UTI isolates. Acquired resistance genes showed aac(6')-II and aac(3)-Id were linked to Bangladeshi UTI, rmtF associated with Indian UTI, and crpP confined to MK exoU isolates. Virulence profiling showed exoU enrichment in pldA, pvdY, and csrA, whereas exoS was associated with pilC, pilV, pilW, pilY2, and pilA. Collectively, these results indicate that exoU and exoS isolates differ in both their resistance and virulence profiles, while also showing evidence of geographic and infection-site-specific adaptation. (© 2026. The Author(s).) |
| Competing Interests: | Declarations. Ethics approval: Not applicable. Competing interests: The authors declare no competing interests. |
| References: | J Clin Microbiol. 2001 Aug;39(8):2964-6. (PMID: 11474023) Ocul Surf. 2023 Apr;28:351-363. (PMID: 34419639) Nature. 2013 Apr 25;496(7446):508-12. (PMID: 23552891) Mol Microbiol. 1997 Aug;25(3):547-57. (PMID: 9302017) Front Microbiol. 2019 Jul 31;10:1718. (PMID: 31417515) Antimicrob Agents Chemother. 2005 Aug;49(8):3382-6. (PMID: 16048951) Front Microbiol. 2022 Aug 09;13:965053. (PMID: 36016776) Pathog Dis. 2013 Apr;67(3):159-73. (PMID: 23620179) Nat Protoc. 2008;3(2):163-75. (PMID: 18274517) Infect Drug Resist. 2022 Jan 14;15:141-151. (PMID: 35058697) Sci Rep. 2020 Jan 10;10(1):120. (PMID: 31924850) Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15055-60. (PMID: 23980177) mBio. 2019 Aug 20;10(4):. (PMID: 31431558) Nucleic Acids Res. 2003 Jul 1;31(13):3812-4. (PMID: 12824425) Microbiol Spectr. 2023 Jun 15;11(3):e0508722. (PMID: 37191517) J Biol Chem. 2003 Oct 17;278(42):41326-32. (PMID: 12915403) Antimicrob Agents Chemother. 2018 May 25;62(6):. (PMID: 29581123) Signal Transduct Target Ther. 2022 Jun 25;7(1):199. (PMID: 35752612) Antimicrob Agents Chemother. 2003 May;47(5):1584-8. (PMID: 12709326) Ocul Surf. 2026 Jan;39:49-57. (PMID: 41422890) J Bacteriol. 2005 May;187(10):3496-501. (PMID: 15866937) J Glob Antimicrob Resist. 2026 Jan;46:158-161. (PMID: 41380995) Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404) Microorganisms. 2023 May 19;11(5):. (PMID: 37317319) Surg Infect (Larchmt). 2016 Oct;17(5):610-4. (PMID: 27441791) Pharmaceutics. 2024 Aug 16;16(8):. (PMID: 39204419) Nucleic Acids Res. 2025 Jan 6;53(D1):D516-D522. (PMID: 39535043) Clin Exp Optom. 2018 Mar;101(2):162-171. (PMID: 29044738) Pharmacotherapy. 2005 Oct;25(10):1353-64. (PMID: 16185180) Microb Genom. 2016 Apr 29;2(4):e000056. (PMID: 28348851) Front Microbiol. 2018 Oct 29;9:2578. (PMID: 30420847) PLoS Biol. 2022 Nov 18;20(11):e3001878. (PMID: 36399436) Environ Microbiol. 2011 Jul;13(7):1655-65. (PMID: 21450006) Antibiotics (Basel). 2022 Sep 19;11(9):. (PMID: 36140050) Microorganisms. 2024 Mar 22;12(4):. (PMID: 38674581) Microb Genom. 2021 Nov;7(11):. (PMID: 34739369) Southeast Asian J Trop Med Public Health. 2012 Jan;43(1):116-23. (PMID: 23082561) Nucleic Acids Res. 2025 Jan 6;53(D1):D871-D877. (PMID: 39470738) Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7707-7712. (PMID: 28673999) Antimicrob Agents Chemother. 2007 Oct;51(10):3531-6. (PMID: 17682106) Cornea. 2023 Jul 1;42(7):837-846. (PMID: 35942533) Microbiol Res. 2021 May;246:126719. (PMID: 33582609) PLoS Comput Biol. 2017 Jun 8;13(6):e1005595. (PMID: 28594827) J Microbiol Biotechnol. 2025 Sep 24;35:e2505031. (PMID: 41016818) J Med Microbiol. 2022 Mar;71(3):. (PMID: 35275806) J Med Microbiol. 2008 Dec;57(Pt 12):1539-1546. (PMID: 19018027) Antibiotics (Basel). 2020 Sep 14;9(9):. (PMID: 32937932) Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296. (PMID: 33885785) Nat Commun. 2025 Jan 2;16(1):19. (PMID: 39746975) Infect Immun. 2004 Dec;72(12):6969-77. (PMID: 15557619) Infect Drug Resist. 2022 Jul 16;15:3801-3814. (PMID: 35875614) Cureus. 2024 Mar 14;16(3):e56154. (PMID: 38495968) J Bacteriol. 1992 May;174(10):3196-203. (PMID: 1577689) Eur J Clin Microbiol Infect Dis. 2025 Jul;44(7):1629-1641. (PMID: 40261546) EMBO J. 2003 Jun 16;22(12):2959-69. (PMID: 12805211) Antimicrob Agents Chemother. 2005 Feb;49(2):479-87. (PMID: 15673721) Future Microbiol. 2022 Apr;17:465-481. (PMID: 35289684) J Infect Public Health. 2009;2(3):101-11. (PMID: 20701869) Emerg Infect Dis. 2015 Nov;21(11):2059-62. (PMID: 26488937) J Antimicrob Chemother. 2018 Jun 1;73(6):1724-1726. (PMID: 29547943) Antimicrob Agents Chemother. 2003 May;47(5):1746-8. (PMID: 12709352) J Antimicrob Chemother. 2020 Dec 1;75(12):3491-3500. (PMID: 32780112) Eur J Clin Microbiol Infect Dis. 2026 Jan;45(1):79-101. (PMID: 41108437) Microb Drug Resist. 2019 Jul/Aug;25(6):813-823. (PMID: 30807251) Crit Care. 2014 Dec 13;18(6):668. (PMID: 25672496) EMBO Rep. 2021 Feb 3;22(2):e50613. (PMID: 33345425) Cells. 2023 Jan 03;12(1):. (PMID: 36611990) PLoS One. 2018 Sep 28;13(9):e0204936. (PMID: 30265709) Cornea. 2008 Apr;27(3):320-6. (PMID: 18362661) Mol Biol Evol. 2018 Feb 1;35(2):518-522. (PMID: 29077904) Bioinformatics. 2013 Apr 15;29(8):1072-5. (PMID: 23422339) Science. 2000 May 19;288(5469):1251-4. (PMID: 10818002) Mol Microbiol. 2001 Jan;39(2):291-303. (PMID: 11136451) Clinics (Sao Paulo). 2011;66(9):1519-22. (PMID: 22179152) Int J Antimicrob Agents. 2009 Nov;34(5):414-8. (PMID: 19656662) Ann N Y Acad Sci. 2015 Sep;1354:12-31. (PMID: 26190223) Iran J Pathol. 2021 Fall;16(4):426-432. (PMID: 34567192) Biology (Basel). 2022 Nov 25;11(12):. (PMID: 36552220) Infect Immun. 2000 Jul;68(7):3998-4004. (PMID: 10858214) FEBS Lett. 2015 Apr 2;589(8):890-6. (PMID: 25747138) BMC Genomics. 2015 Oct 30;16:883. (PMID: 26519161) PLoS One. 2025 Feb 24;20(2):e0302352. (PMID: 39993019) Exp Eye Res. 2026 Apr;265:110868. (PMID: 41548832) J Infect Chemother. 2016 Apr;22(4):216-20. (PMID: 26809217) Sci Rep. 2019 Jul 26;9(1):10874. (PMID: 31350412) Eur J Clin Microbiol Infect Dis. 2026 Mar;45(3):641-649. (PMID: 41212467) Auris Nasus Larynx. 2017 Jun;44(3):258-265. (PMID: 27461174) Antimicrob Agents Chemother. 2000 Mar;44(3):710-2. (PMID: 10681343) Sci Rep. 2018 Oct 23;8(1):15668. (PMID: 30353070) Eur J Clin Microbiol Infect Dis. 2026 Jul;45(7):1867-1890. (PMID: 41872433) Clin Infect Dis. 2015 Feb 15;60(4):539-48. (PMID: 25378459) Germs. 2016 Dec 2;6(4):132-138. (PMID: 28053916) Wellcome Open Res. 2018 Sep 24;3:124. (PMID: 30345391) Mol Biol Evol. 2026 May 01;43(5):. (PMID: 42085559) PLoS One. 2017 May 26;12(5):e0178178. (PMID: 28552972) Interdiscip Perspect Infect Dis. 2012;2012:843509. (PMID: 22973307) Drug Resist Updat. 2003 Jun;6(3):137-45. (PMID: 12860461) Cell Host Microbe. 2014 May 14;15(5):600-10. (PMID: 24832454) J Pediatr Urol. 2016 Feb;12(1):36.e1-6. (PMID: 26320394) Nucleic Acids Res. 2015 Feb 18;43(3):e15. (PMID: 25414349) Microb Drug Resist. 2003 Winter;9(4):323-8. (PMID: 15000738) |
| Contributed Indexing: | Keywords: Pseudomonas aeruginosa; exoS; exoU; Antibiotic resistance; Microbial keratitis; Urinary tract infection; Virulence factors |
| Substance Nomenclature: | 0 (Anti-Bacterial Agents) 0 (Virulence Factors) 0 (Bacterial Proteins) EC 2.4.2.31 (Pseudomonas aeruginosa Exotoxin A) 5E8K9I0O4U (Ciprofloxacin) 0 (pseudomonas exoprotein A protein, Pseudomonas aeruginosa) 0 (Bacterial Toxins) 6GNT3Y5LMF (Levofloxacin) |
| Entry Date(s): | Date Created: 20261012 Date Completed: 20261012 Latest Revision: 20261015 |
| Update Code: | 20261015 |
| PubMed Central ID: | PMC13658543 |
| DOI: | 10.1007/s11274-026-05320-2 |
| PMID: | 42862478 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!